ClinicalTrials.gg
CompletedNCT03217565Updated Feb 11, 2025Results posted

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

A Phase 1 interventional study of IV Tedizolid Phosphate and Oral Suspension Tedizolid Phosphate in Gram-Positive Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 30 sites in 5 countries. Open to participants aged 1 Day to 24 Months. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
1 Day to 24 Months
Sex
All
01

Study summary

The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to pediatric participants, full-term neonates, and preterm neonates.

Read the detailed description

Per protocol, PK analysis in Part A Group 1 will be conducted across ages in Cohorts 1 and 2 combined: Part A Group 1 Cohort 1 + Cohort 2: 28 days to \<24 months.

02

Conditions studied

  • Gram-Positive Infections
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is receiving prophylaxis for or has a confirmed or suspected infection with gram-positive bacteria and receiving concurrent antibiotic treatment with gram -positive antibacterial activity.
  • Is at least 1 kg in weight.
  • Is in stable condition as determined from medical history, physical examination, (ECG), vital signs, and clinical laboratory evaluations.
  • Has no ECG abnormalities.
  • Has sufficient vascular access to receive trial drug, and allow for required blood draws.
  • Is able to receive medication by mouth, for those dosed with oral suspension; dose administration via feeding tube is acceptable.

Exclusion criteria

Exclusion Criteria:

  • Has a history of seizures, other than febrile seizures, cardiac arrhythmia or condition, moderate or severe renal impairment, or any physical condition that could interfere with the interpretation of the study results, as determined by the Investigator.
  • Has used rifampin within 14 days prior to dosing.
  • Has used or will be using proton pump inhibitors, H2 blockers, or antacids (for participants in Part B, i.e, oral suspension dose) at any time from 24 hours prior to dosing through 24 hours after dosing..
  • Has a recent (3-month) history or current infection with viral hepatitis or other significant hepatic disease.
  • Has a history of drug allergy or to oxazolidinones.
  • Has had significant blood loss.
  • Need for oral administration of topotecan, rosuvastatin, irinotecan, or methotrexate during administration of oral study drug.
  • Used monoamine oxidase inhibitors (MAOIs) or serotonergic agents including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin 5-hydroxytryptamine receptor agonists (triptans), meperidine, or buspirone within 14 days prior to study, or planned use while on study.
  • Has received another product within the 30 days prior to enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 days to <6 months

    Pediatric participants 28 days to \<6 months of age will receive a single dose (SD) intravenous (IV) infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: IV Tedizolid Phosphate

  • Experimental
    Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 months to <24 months

    Pediatric participants 6 months to \<24 months of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: IV Tedizolid Phosphate

  • Experimental
    Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (full term) birth to <28 days

    Full term (FT) neonates from birth to \<28 days of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: IV Tedizolid Phosphate

  • Experimental
    Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (full term) birth to <28 days

    FT neonates from birth to \<28 days of age will receive multiple dose (MD) IV infusions of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg, administered twice daily for 3 days.

    Drug: IV Tedizolid Phosphate

  • Experimental
    Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (preterm) birth to <28 days

    Preterm (PT) neonates from birth to \<28 days of age will receive an SD IV infusion of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: IV Tedizolid Phosphate

  • Experimental
    Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (preterm) birth to <28 days

    PT neonates from birth to \<28 days of age will receive MD IV infusions of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg, administered twice daily for 3 days.

    Drug: IV Tedizolid Phosphate

  • Experimental
    Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 days to <24 months

    Pediatric participants 28 days to \<24 months of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: Oral Suspension Tedizolid Phosphate

  • Experimental
    Part B Group 5: Single Dose Oral Tedizolid Phosphate (full term) birth to <28 days

    FT neonates from birth to \<28 days of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: Oral Suspension Tedizolid Phosphate

  • Experimental
    Part B Group 6: Single Dose Oral Tedizolid Phosphate (preterm) birth to <28 days

    PT neonates from birth to \<28 days of age will receive an SD oral suspension of tedizolid phosphate according to body weight: 3 mg/kg for body weight \<10 kg or 2.5 mg/kg for body weight 10 to \<30 kg.

    Drug: Oral Suspension Tedizolid Phosphate

Interventions

  • A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.

  • DrugOral Suspension Tedizolid Phosphate

    A single dose of tedizolid phosphate administered as an oral suspension.

06

What researchers measure

Primary outcomes

  1. Part A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

    AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of pharmacokinetic (PK) outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-last for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  2. Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

    AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-inf for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  3. Part A: Maximum Concentration (Cmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

    Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Cmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  4. Part A: Time to Reach Maximum Concentration (Tmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

    Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Tmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  5. Part A: Apparent Terminal Half-life (t½) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

    t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate t½ for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  6. Part A: AUC0-last of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

    AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-last for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  7. Part A: AUC0-inf of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

    AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-inf for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this endpoint and were excluded from this protocol-specified analysis.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  8. Part A: Cmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

    Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Cmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  9. Part A: Tmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

    Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Tmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  10. Part A: t½ of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

    t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate t½ for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  11. Part A: AUC0-24 of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate [AUC0-last]

    AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-last for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  12. Part A: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

    AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  13. Part A: Cmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

    Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Cmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  14. Part A: Tmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

    Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Tmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  15. Part A: t½ of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

    t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, t½ for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 1.5, 3, 6, 12 and 24 hours post start of dosing

  16. Part A: AUC0-12 of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate [AUC0-last]

    AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. This was analyzed in the per protocol population consisting of the subset of participants who complied with the protocol sufficiently to ensure that these data would be likely to exhibit treatment effects, based on the underlying scientific model and had data available for this endpoint. As specified in the protocol, AUC0-last for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  17. Part A: Cmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

    Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  18. Part A: Tmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

    Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  19. Part A: AUC0-inf of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

    AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single concentration listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, AUC0-inf of tedizolid metabolite could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in single dose (Part A Group 1\[Cohorts 1 and 2\],Group 2 Cohort 1, Group 3 Cohort 1; Part B\[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  20. Part A: t½ of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

    t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, t½ could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, t½ for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

    Time frame: Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

  21. Part B: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension [AUC0-last]

    AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-last for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing

  22. Part B: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

    AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-inf for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing

  23. Part B: Cmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

    Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing

  24. Part B: Tmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

    Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing

  25. Part B: t½ of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

    t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, t½ for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

    Time frame: 1, 3, 5, 8, 12, and 24 hours post start of dosing

Secondary outcomes

  1. Number of Participants With an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing an AE was reported for each arm.

    Time frame: Up to approximately 21 days

  2. Number of Participants That Discontinued Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported for each arm.

    Time frame: Up to approximately 3 days

07

Results

Posted Jul 22, 2024

Participant flow

This study was conducted at 30 centers in 5 countries.

Participant flow — Overall Study
MilestonePart A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Started468494444
Completed468494444
Not completed000000000

Outcome measures

PrimaryPart A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of pharmacokinetic (PK) outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-last for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · hr*μg/mL
Part A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration (AUC0-last) of Tedizolid Phosphate (Prodrug) After Single-dose IV AdministrationNA ± NANA ± NA—NA ± NA————
PrimaryPart A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate AUC0-inf for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · hr*μg/mL
Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Tedizolid Phosphate (Prodrug) After Single-dose IV AdministrationNA ± NANA ± NA—NA ± NA————
PrimaryPart A: Maximum Concentration (Cmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Cmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · μg/mL
Part A: Maximum Concentration (Cmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Maximum Concentration (Cmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV AdministrationNA ± NANA ± NA—NA ± NA————
PrimaryPart A: Time to Reach Maximum Concentration (Tmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate Tmax for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Median · hr
Part A: Time to Reach Maximum Concentration (Tmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Time to Reach Maximum Concentration (Tmax) of Tedizolid Phosphate (Prodrug) After Single-dose IV AdministrationNA (NA to NA)NA (NA to NA)—NA (NA to NA)————
PrimaryPart A: Apparent Terminal Half-life (t½) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration

t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK outcomes in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, tedizolid phosphate t½ for multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · hr
Part A: Apparent Terminal Half-life (t½) of Tedizolid Phosphate (Prodrug) After Single-dose IV Administration
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Apparent Terminal Half-life (t½) of Tedizolid Phosphate (Prodrug) After Single-dose IV AdministrationNA ± NANA ± NA—NA ± NA————
PrimaryPart A: AUC0-last of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

AUC0-last of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-last for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Geometric mean · hr*μg/mL
Part A: AUC0-last of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: AUC0-last of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration————NA ± NA———
PrimaryPart A: AUC0-inf of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

AUC0-inf of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate AUC0-inf for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this endpoint and were excluded from this protocol-specified analysis.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Geometric mean · hr*μg/mL
Part A: AUC0-inf of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: AUC0-inf of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration————NA ± NA———
PrimaryPart A: Cmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

Cmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Cmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Geometric mean · μg/mL
Part A: Cmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Cmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration————NA ± NA———
PrimaryPart A: Tmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

Tmax of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate Tmax for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Median · hr
Part A: Tmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Tmax of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration————NA (NA to NA)———
PrimaryPart A: t½ of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration

t½ of tedizolid phosphate was quantified in participants receiving tedizolid phosphate. As specified in the protocol, tedizolid phosphate t½ for single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1) were not included in this outcome and have been reported separately in the record. Tedizolid phosphate PK analysis was not planned or conducted in Part B (Groups 4, 5, 6), per protocol. Participants in Group 2 Cohort 2 study arm did not meet the criteria for PK per protocol analysis population for this outcome and were excluded from this protocol-specified analysis.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Geometric mean · hr
Part A: t½ of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: t½ of Tedizolid Phosphate (Prodrug) After Multiple-dose IV Administration————NA ± NA———
PrimaryPart A: AUC0-24 of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate [AUC0-last]

AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-last for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · hr*μg/mL
Part A: AUC0-24 of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate [AUC0-last]
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: AUC0-24 of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate [AUC0-last]13.6 ± 42.48.23 ± 115.9—15.6 ± 17.6————
PrimaryPart A: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · hr*μg/mL
Part A: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate14.3 ± 40.49.21 ± 128.2—17.8 ± 20.9————
PrimaryPart A: Cmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Cmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · μg/mL
Part A: Cmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Cmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate2.19 ± 51.00.962 ± 71.9—1.35 ± 44.5————
PrimaryPart A: Tmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, Tmax for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Median · hr
Part A: Tmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Tmax of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate1.33 (1.00 to 1.58)1.41 (1.00 to 2.50)—1.50 (1.08 to 6.53)————
PrimaryPart A: t½ of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate

t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. Protocol specified analysis of PK endpoints in Group 1 was done irrespective of age (28 days to \<24 months, across ages in Cohorts 1 and 2). As specified in the protocol, t½ for tedizolid metabolite in multiple dose (Part A Group 2 Cohort 2, Group 3 Cohort 2) and Part B (Groups 4, 5, 6) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 1.5, 3, 6, 12 and 24 hours post start of dosing
Reported as:
Geometric mean · hr
Part A: t½ of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: t½ of Tedizolid (Active Metabolite) After Single-dose IV Administration of Tedizolid Phosphate4.17 ± 47.76.63 ± 38.0—7.08 ± 41.2————
PrimaryPart A: AUC0-12 of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate [AUC0-last]

AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. This was analyzed in the per protocol population consisting of the subset of participants who complied with the protocol sufficiently to ensure that these data would be likely to exhibit treatment effects, based on the underlying scientific model and had data available for this endpoint. As specified in the protocol, AUC0-last for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Number · hr*μg/mL
Part A: AUC0-12 of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate [AUC0-last]
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: AUC0-12 of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate [AUC0-last]——10.5—7.48———
PrimaryPart A: Cmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Number · μg/mL
Part A: Cmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate
μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Cmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate——1.82—1.69———
PrimaryPart A: Tmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing
Reported as:
Number · hr
Part A: Tmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part A: Tmax of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate——1.60—1.08———
PrimaryPart A: AUC0-inf of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single concentration listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, AUC0-inf of tedizolid metabolite could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, AUC0-inf for tedizolid metabolite in single dose (Part A Group 1\[Cohorts 1 and 2\],Group 2 Cohort 1, Group 3 Cohort 1; Part B\[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

No measurements were reported for this outcome.

PrimaryPart A: t½ of Tedizolid (Active Metabolite) After Multiple-dose IV Administration of Tedizolid Phosphate

t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach to be used in this noncompartmental analysis would allow data collected to generate single listing. However, protocol-specified PK sampling did not characterize the terminal elimination phase; therefore, t½ could not be estimated for multiple dose study arms (Part A Group 2 Cohort 2 and Part A Group 3 Cohort 2). As specified in the protocol, t½ for tedizolid metabolite in single dose (Part A Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 3 Cohort 1; Part B \[Groups 4, 5, 6\]) were not included in this endpoint and have been reported separately in the record.

Time frame:
Day 3: pre-dose, 1, 1.5, 3, 6 and 12 hours post start of dosing

No measurements were reported for this outcome.

PrimaryPart B: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension [AUC0-last]

AUC0-last of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-last for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 3, 5, 8, 12, and 24 hours post start of dosing
Reported as:
Number · hr*μg/mL
Part B: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension [AUC0-last]
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part B: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension [AUC0-last]—————7.929.2514.9
PrimaryPart B: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

AUC0-inf of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, AUC0-inf for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 3, 5, 8, 12, and 24 hours post start of dosing
Reported as:
Number · hr*μg/mL
Part B: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
hr*μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part B: AUC0-inf of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension—————8.369.4422.1
PrimaryPart B: Cmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

Cmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single concentration listing. As specified in the protocol, Cmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 3, 5, 8, 12, and 24 hours post start of dosing
Reported as:
Number · μg/mL
Part B: Cmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
μg/mLGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part B: Cmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension—————1.320.8991.22
PrimaryPart B: Tmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

Tmax of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, Tmax for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 3, 5, 8, 12, and 24 hours post start of dosing
Reported as:
Number · hr
Part B: Tmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part B: Tmax of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension—————13.038
PrimaryPart B: t½ of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension

t½ of tedizolid (metabolite) was quantified in participants receiving tedizolid phosphate. The per protocol statistical approach used in this noncompartmental analysis allowed data collected to generate single listing. As specified in the protocol, t½ for tedizolid metabolite in Part A (Group 1 \[Cohorts 1 and 2\], Group 2 Cohort 1, Group 2 Cohort 2, Group 3 Cohort 1, Group 3 Cohort 2) were not included in this endpoint and have been reported separately in the record.

Time frame:
1, 3, 5, 8, 12, and 24 hours post start of dosing
Reported as:
Number · hr
Part B: t½ of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension
hrGroup 1 Cohorts 1+2:SD IV Tedizolid Phosphate 28days-<24monthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Part B: t½ of Tedizolid (Active Metabolite) After Single-dose Administration of Tedizolid Phosphate Oral Suspension—————5.733.8213.4
SecondaryNumber of Participants With an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing an AE was reported for each arm.

Time frame:
Up to approximately 21 days
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsPart A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Number of Participants With an Adverse Event (AE)110022101
SecondaryNumber of Participants That Discontinued Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported for each arm.

Time frame:
Up to approximately 3 days
Reported as:
Count of participants · Participants
Number of Participants That Discontinued Study Treatment Due to an AE
ParticipantsPart A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Number of Participants That Discontinued Study Treatment Due to an AE000000000

Adverse events

Collected over Up to approximately 21 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 Months0/4 (0%)1/4 (25%)0/4 (0%)
Part A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 Months0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days0/8 (0%)0/8 (0%)0/8 (0%)
Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days0/4 (0%)0/4 (0%)0/4 (0%)
Part A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 Days0/9 (0%)0/9 (0%)2/9 (22.2%)
Part A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 Days0/4 (0%)0/4 (0%)2/4 (50%)
Part B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 Months0/4 (0%)0/4 (0%)1/4 (25%)
Part B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 Days0/4 (0%)0/4 (0%)0/4 (0%)
Part B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent serious events
Most frequent serious events
EventPart A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
Therapeutic product effect incompleteGeneral disorders1/40/60/80/40/90/40/40/40/4
Most frequent other events
Most frequent other events
EventPart A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 Days
AnaemiaBlood and lymphatic system disorders0/40/60/80/40/91/40/40/40/4
Swelling of eyelidEye disorders0/40/60/80/40/90/41/40/40/4
ConjunctivitisInfections and infestations0/40/60/80/40/91/40/40/40/4
Serratia sepsisInfections and infestations0/40/60/80/40/91/40/40/40/4
Immature granulocyte count increasedInvestigations0/40/60/80/40/90/40/40/41/4
Jaundice neonatalPregnancy, puerperium and perinatal conditions0/40/60/80/40/91/40/40/40/4
RashSkin and subcutaneous tissue disorders0/41/60/80/40/90/40/40/40/4
PneumoniaInfections and infestations0/40/60/80/41/90/40/40/40/4
Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders0/40/60/80/41/90/40/40/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(Days)Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 DaysTotal
Mean51.3 ± 9.9420.7 ± 167.18.3 ± 9.411.8 ± 11.39.9 ± 7.92.0 ± 1.2289.0 ± 165.513.0 ± 11.76.5 ± 6.488.8 ± 165.7
Sex: Female, Male
Sex: Female, Male(Participants)Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 DaysTotal
Female22513220118
Male24336224329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 DaysTotal
Hispanic or Latino00733202320
Not Hispanic or Latino46115242126
Unknown or Not Reported0000100001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Group 1 Cohort 1: Single Dose IV Tedizolid Phosphate 28 Days to <6 MonthsPart A Group 1 Cohort 2: Single Dose IV Tedizolid Phosphate 6 Months to <24 MonthsPart A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 DaysPart A Group 3 Cohort 1: Single Dose IV Tedizolid Phosphate (Preterm) Birth to <28 DaysPart A Group 3 Cohort 2: Multiple Dose IV Tedizolid Phosphate IV (Preterm) Birth to <28 DaysPart B Group 4: Single Dose Oral Tedizolid Phosphate 28 Days to <24 MonthsPart B Group 5: Single Dose Oral Tedizolid Phosphate (Full Term) Birth to <28 DaysPart B Group 6: Single Dose Oral Tedizolid Phosphate (Preterm) Birth to <28 DaysTotal
American Indian or Alaska Native0001000001
Asian0000000000
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1000000001
White35216242126
More than one race01623202319
Unknown or Not Reported0000000000
08

Study locations

30 sites
  • Arkansas Children's Hospital ( Site 1012)
    Little Rock, Arkansas 72202, United States
  • Children's Hospital of Orange County ( Site 1001)
    Orange, California 92868, United States
  • Sharp Memorial Hospital ( Site 1021)
    San Diego, California 92123, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 1022)
    Chicago, Illinois 60611, United States
  • Our Lady of the Lake Regional Medical Center. ( Site 1004)
    Baton Rouge, Louisiana 70808, United States
  • Saint Louis Children's Hospital ( Site 1020)
    Saint Louis, Missouri 63110, United States
  • Primary Children's Hospital ( Site 1000)
    Salt Lake City, Utah 84113, United States
  • Medical Center - 1- Sevlievo EOOD ( Site 2207)
    Sevlievo, Gabrovo 5400, Bulgaria
  • MHAT Sv. Ivan Rilski EOOD ( Site 2201)
    Kozloduy, Vratsa 3320, Bulgaria
  • UMHAT Deva Maria ( Site 2208)
    Burgas, 8127, Bulgaria
  • MHAT Dr. Tota Venkova-Pediatrics ( Site 2218)
    Gabrovo, 5300, Bulgaria
  • MHAT "Dr. Stamen Iliev" Montana ( Site 2215)
    Montana, 3400, Bulgaria
  • MHAT City Clinic Sv. Georgi EOOD ( Site 2202)
    Montana, 3400, Bulgaria
  • UMHAT Dr. Georgi Stranski EAD ( Site 2211)
    Pleven, 5800, Bulgaria
  • MHAT Rousse-Neonatology ( Site 2213)
    Ruse, 7002, Bulgaria
  • Multiprofile Hospital for Active Treatment - Ruse ( Site 2204)
    Ruse, 7002, Bulgaria
  • UMHAT Kanev AD ( Site 2209)
    Ruse, 7002, Bulgaria
  • MHAT Dr. Ival Seliminski ( Site 2212)
    Sliven, 8800, Bulgaria
  • Hospital San Vicente Fundacion ( Site 1103)
    Medellin, Antioquia 050010, Colombia
  • Clinica de la Costa S.A.S. ( Site 1106)
    Barranquilla, Atlantico 080020, Colombia
  • Fundacion Hospital Infantil Universitario de San Jose ( Site 1107)
    Bogota, Distrito Capital De Bogota 111221, Colombia
  • Fundacion Valle del Lili ( Site 1102)
    Cali, Valle Del Cauca 760032, Colombia
  • Akershus Universitetssykehus HF ( Site 1604)
    Loerenskog, Akershus 1478, Norway
  • Haukeland Universitetssjukehus ( Site 1602)
    Bergen, Hordaland 5021, Norway
  • Stavanger Universitetssykehus, Helse Stavanger ( Site 1601)
    Stavanger, Rogaland 4011, Norway
  • St. Olavs Hospital. ( Site 1600)
    Trondheim, Sor-Trondelag 7006, Norway
  • University Hospital Southampton NHS Foundation Trust ( Site 1700)
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Alder Hey Childrens NHS Foundation Trust Hospital ( Site 1703)
    Liverpool, Lancashire L12 2AP, United Kingdom
  • Royal Victoria Infirmary ( Site 1702)
    Newcastle, Newcastle Upon Tyne NE1 4LP, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust ( Site 1704)
    Oxford, Oxfordshire OX3 9DU, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Mar 2023, 49 months.

Results were first posted in Jul 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 14, 2017
StartActual
Feb 6, 2019
Primary completionActual
Mar 18, 2023
CompletionActual
Apr 6, 2023
Results first posted
Jul 22, 2024
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03217565
Responsible party
Sponsor
First posted
Jul 14, 2017
Start date
Feb 6, 2019
Primary completion
Mar 18, 2023
Completion
Apr 6, 2023
Results posted
Jul 22, 2024
Last update
Feb 11, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion